Abstract
Recent research showed group B patients express higher mortality compared to group C patients when GOLD A-D grouping is used. We aimed to compare the prognostic accuracy of three GOLD classification systems, I–IV (“pre-2011”), A-D (“2011–2016”) and A-D (“2017–present”) in relation to mortality, exacerbation risk, quality of life (QoL) assessment and specific treatments use in a real-life COPD cohort. We used the data of 720 patients from the Czech Multicenter Research Database of COPD. Four-year mortality and time-to-exacerbation using the GOLD “pre-2011”, “2011–2016” and “2017–present” classification schemes were assessed. Moreover, distribution of specific treatments use and QoL measures were analyzed. The GOLD I-IV classification system showed gradual increase in 4-year mortality across the stages (GOLD II 18.8%, III 28.5%, IV 38.7%) (p = 0.001). Using the A-D “2011–2016” classification scheme, group C patients had lower mortality (16.7%) than group B (18.7%) (p = 0.009). The A-D “2017–present” classification showed higher mortality in group B (25.5%) compared to group C (20%) (p = 0.05). For additional outcomes, the GOLD I–IV scheme showed highest match between the calculated 4-year exacerbation risk and QoL measures and GOLD stage/grouping. In terms of specific treatment distributions, various patterns for each GOLD classification system were observed with best match of GOLD “2017–present” system to the layout of GOLD groups and categories. We conclude the GOLD I–IV classification system had the highest accuracy related to mortality, QoL measures and exacerbation risk prediction, while the A-D “2017–present” scheme was most accurate within severity of symptoms prediction reflected also by more frequent specific treatments use.
References
GOLD 2017 Global Strategy for the Diagnosis, Management and prevention of COPD. global initiative for chronic obstructive lung disease. http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/. Accessed 12 July 2018
Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P et al (2007) Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176:532–555
Agusti A, Hurd S, Jones P, Fabbri LM, Martinez F, Vogelmeier C et al (2013) FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. Eur Respir J 42:1391–1401
Global Strategy for Diagnosis, Management, and Prevention of COPD – (2016) Global Initiative for Chronic Obstructive Lung Disease. http://goldcopd.org/global-strategy-diagnosis-management-prevention-copd-2016/. Accessed 12 July 2018
Lange P, Marott JL, Vestbo J, Olsen KR, Ingebrigtsen TS, Dahl M et al (2012) Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med 186:975–981
Tudoric N, Koblizek V, Miravitlles M, Valipour A, Milenkovic B, Barczyk A et al (2017) GOLD 2017 on the way to a phenotypic approach? Analysis from the phenotypes of COPD in central and Eastern Europe (POPE) cohort. Eur Respir J 49:1602518. https://doi.org/10.1183/13993003.02518-2016
Cabrera López C, Casanova Macario C, Marín Trigo JM, de-Torres JP, Sicilia Torres R, González JM et al (2018) Comparison of the 2017 and 2015 global initiative for chronic obstructive lung disease reports. Impact on grouping and outcomes. Am J Respir Crit Care Med 197:463–469
Novotna B, Koblizek V, Zatloukal J, Plutinsky M, Hejduk K, Zbozinkova Z et al (2014) Czech multicenter research database of severe COPD. Int J Chron Obstruct Pulmon Dis 9:1265–1274. https://doi.org/10.2147/COPD.S71828
Agusti A, Edwards LD, Celli B, Macnee W, Calverley PM, Müllerova H et al (2013) ECLIPSE Investigators. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J 42:636–646
Koblizek V, Milenkovic B, Barczyk A, Tkacova R, Somfay A, Zykov K et al (2017) Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE Study. Eur Respir J 49:1601446. https://doi.org/10.1183/13993003.01446-2016
Brat K, Plutinsky M, Hejduk K, Svoboda M, Popelkova P, Zatloukal J et al (2018) Respiratory parameters predict poor outcome in COPD patients, category GOLD 2017 B. Int J Chron Obstruct Pulmon Dis 13:1037–1052. https://doi.org/10.2147/COPD.S147262
Golpe R, Suárez-Valor M, Martín-Robles I, Sanjuán-López P, Cano-Jiménez E, Castro-Añón O et al (2018) Mortality in COPD patients according to clinical phenotypes. Int J Chron Obstruct Pulmon Dis 13:1433–1439. https://doi.org/10.2147/COPD.S159834
Miravitlles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA et al (2017) Spanish guidelines for management of chronic obstructive pulmonary disease (GesEPOC) 2017. Pharmacological treatment of stable phase. Arch Bronconeumol 53:324–335. https://doi.org/10.1016/j.arbres.2017.03.018
Soler-Cataluña JJ, Martínez-García MA, Román Sánchez P, Salcedo E, Navarro M, Ochando R (2005) Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60:925–931
Groenewegen KH, Schols AM, Wouters EF (2003) Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 124:459–467
Almagro P, Calbo E, Ochoa de Echagüen A, Barreiro B, Quintana S, Heredia JL, Garau J (2002) Mortality after hospitalization for COPD. Chest 121(5):1441–1448
Acknowledgements
We thank the physicians of participating centers of the CMRD project.
Funding
This research was funded by Ministry of Health of the Czech Republic (15/14/NAP; 5/15/NAP; UHHK 00179906 and FNBr 65269705) and by a consortium of pharmaceutical companies (Angelini CZ, AstraZeneca CZ, Boehringer Ingelheim CZ, Cipla CZ, CSL Behring CZ, GSK CZ, Novartis CZ and Sandoz CZ).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflicts of interest in relation to the presented work.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Plutinsky, M., Brat, K., Svoboda, M. et al. Prognostic Accuracy of Three COPD Classification Systems in Relation to Long-Term Mortality of COPD Patients: A Prospective Multicenter Study. Lung 197, 173–179 (2019). https://doi.org/10.1007/s00408-019-00196-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00408-019-00196-6